GATA-3 expression is crucial for T cell development and peaks during commitment to the T cell lineage, midway through the CD4
G ata3 is required for T cell development, but the mechanisms by which it works are only partially understood. Gata3 is expressed in a number of embryonic tissues as well as in the thymus, and the germline knockout generates an embryonic lethal phenotype before the earliest T development stages, between embryonic day (E)11 and E12 in Gata3 knockout pups (1) . Rag2 2/2 blastocyst complementation experiments show that Gata3-null embryonic stem cells can contribute to all hematopoietic lineages except the T lineage (2) (3) (4) (5) . Experiments showing that antisense oligonucleotides to Gata3 could block appearance of CD3 + cells in fetal thymic organ culture provided initial evidence that GATA-3 acts after thymic entry (6) . GATA-3 is also required for generation of the earliest intrathymic precursors (7) , and in some conditions regulates self-renewal behavior of prethymic stem cells as well (8, 9) . Poor viability of the earliest T cell precursors when GATA-3 is removed prethymically (7) has limited exploration of the role GATA-3 plays in T cell specification and commitment, and Lck-Cre deletes a conditional allele too late to probe a role in lineage commitment as such (10) . However, recent work has linked GATA-3 to the important decision of T cell precursors to eliminate B cell potential in the double negative (DN) stages 1 and 2 (11) . The present study was undertaken to introduce stage-specific, acute, early perturbations of GATA-3 that could shed light on its actions between thymic entry and commitment.
Ideally, the roles of GATA-2 could be inferred from its target genes. GATA-3 binding sites have been mapped across the genome in CD4 + CD8 + thymocytes and earlier CD4 2 CD8 2 (DN) precursors (12, 13) . However, the distribution of sites detected has turned out to be variable according to stage, implying that GATA-3 regulates different target genes at different points in development. Complementing GATA-3-deficient cells with retroviral GATA-3 is also challenging because GATA-3 overexpression is as toxic for early T cell precursors as loss of GATA-3 (14) . In this study, therefore, we have retrovirally introduced short hairpin RNA (shRNA) into precursors undergoing T lineage differentiation in vitro (15, 16) to impose loss of function at specific precommitment, pro-T cell stages, and we have examined the effects of acute Gata3 deletion at short time scales. We show that a critical level of GATA-3 activity is needed to progress through commitment, and demonstrate that GATA-3 contributes directly and uniquely to T lineage commitment through two different mechanisms.
Materials and Methods
Mice C57BL/6 (B6), B6D2 F 2 , or Em-Bcl-2-25 (Bcl-2-tg) (17) mice were used. B6 or Em-Bcl2-25 (Bcl2-tg) fetal mice were generated in our colony, and B6 3 DBA/2 (B6D2) F 2 embryos were obtained from the California Institute of Technology Genetically Engineered Mouse Service. ROSA26R-enhanced yellow fluorescent protein (EYFP) reporter mice for Cre-mediated excision (18) were bred from stock donated by Dr. Frank Costantini (Columbia University). Gata-3 fl/fl mice (10) were bred from stock provided by Dr. I-Cheng Ho. Spi1 fl/fl (PU.1 floxed) mice were provided by Dr. Stephen Nutt (19) . Bcl11b fl/fl (Bcl11b floxed) mice were previously described (20) . ROSA26-Cre-ERT2 mice were generated in our colony by crossing PLBD (Bcl11b fl/fl ;ROSA26-Cre-ERT2) mice, provided by Dr. Pentao Liu (21) , to B6 mice. To control the timing of Gata3 deletion, these mice were further crossed to Gata-3 fl/fl mice to generate Gata-3 fl/fl
;ROSA26-Cre-ERT2 mice. Note that unlike the ROSA26R-EYFP Cre recombinase reporter strains, these mice express Cre-ERT2 constitutively, but the nuclear localization and activity of the Cre protein depend on tamoxifen treatment. All animals were bred, maintained under specific pathogen-free conditions, genotyped, and euthanized using Institutional Animal Care and Use Committee-approved protocols.
Cell lines
Adh.2C2, the pro-T cell-like Adh.2C2 cell line, originally subcloned from the SCID.adh cell line (22) , was generated and maintained as previously described (23) . The murine macrophage-like cell line RAW264.7 was used as a negative control for specificity of GATA-3 intracellular staining. OP9 stromal cell lines, which either did (OP9-DL1, OP9-DL4) or did not (OP9-control) express Delta-like ligands, were obtained from J.C. Zúñiga-Pfl€ ucker and cultured as previously described (15, 16, 24) .
Fetal liver-derived DN cells
E13.5-14 fetal liver (FL) was obtained from timed pregnancies of mice of the indicated genotypes. Differentiated cells were depleted using a mixture of biotinylated Abs specific for Ter119, Gr-1, F4/80, and CD19 (lineage [Lin] mixture) using tube adherence to a block magnet followed by a further depletion step on a MACS Miltenyi LS column (Miltenyi Biotec). They were then sorted for c-Kit /plate) were added to 10-cm confluent plates of OP9-DL1 or OP9-control stroma and cultured for 6-7 d (OP9-DL1 condition). Cells were recovered from these cultures and infected overnight with retroviral vectors (performed as previously described) (25) . From these transduced pools, ETP, DN2, and DN3 FLDN cells were sorted based on expression of GFP, c-Kit, CD25, and CD44, with CD45 to exclude stromal cells, prior to subsequent culture. For comparison, in vivo ETP, DN2, DN3, and DN4 cells were sorted from E14.5 fetal thymus (FT) or from the thymus of 4-to 6-wkold adult mice after magnetic bead depletion with Lin mixture supplemented with Abs against TCRb, TCRgd, CD8, NK1.1, and CD11b (Mac1), or using Abs against CD3, CD4, CD8, CD19, and Ter119 for experiments shown in 
Flow cytometry
Flow cytometric analysis was performed on a BD FACSCalibur (BD Biosciences, Mountain View, CA) or MACSQuant (Miltenyi Biotec); sorts were done using either BD FACSVantage SE or the BD FACSAria IIu.
CD45 was used in all cases to discriminate between infected developing hematopoietic cells and OP9-derived stromal cells. The following Ab conjugates (BD Pharmingen and eBioscience) were used: c-Kit-PE, CD27-allophycocyanin, Gr-1-biotin, Ter119-biotin, F4/80-biotin, and CD19-biotin for sorting FL precursors; c-Kit-PE, CD44-PE-Cy5.5, CD45-allophycocyanin, CD25-Alexa Fluor 750 or CD25-allophycocyanin-Cy7, and streptavidin-Alexa Fluor 405 for sorting FT and FLDN precursors.
Four-color staining with intracellular GATA-3 and PU.1 Intracellular staining of transcription factors was performed using a modified version of the BD Cytofix/Cytoperm protocol. Abs used were BD Pharmingen clone L50-823 for GATA-3 and Cell Signaling Technology clone 9G7 for PU.1. Three-color surface staining was performed as normal. Cells were washed once to remove Ab and then pelleted and aspirated. Cells were then resuspended to disrupt the cell pellet prior to addition of 100 ml cold BD Cytofix/Cytoperm and followed by a 20-min incubation on ice. Subsequently, 1 ml/tube 13 PermWash was added and cells were pelleted and resuspended in 100 ml 13 PermWash/tube plus intracellular staining Ab. For both Gata-3 and PU.1, 20 ml Ab per 1 million cells was used, and the equivalent microgram concentration was used for staining with isotype control Ab from the same supplier (BD Pharmingen or Cell Signaling Technology). The cells were incubated with intracellular staining Ab for 30 min at room temperature. Following this, 1 ml 13 PermWash per tube was added to wash. Cells were then resuspended in 2% formaldehyde in PBS and data were acquired by flow cytometry within 1-2 d. Critically, for four-color staining that included staining for intracellular GATA-3 or PU.1, fully stained three-color plus intracellular isotype controls were used to determine accurate, population-specific background levels for GATA-3 and PU.1.
Retroviral vectors and infection of cells
The original Banshee retrovirus was provided by Dr. John Rossi (Beckman Institute of the City of Hope). Dr. Gabriela Hernandez-Hoyos constructed the Banshee-GATA-3 shRNA-expressing virus (called Banshee G3-3W), a derivative of a previously published GATA-3 shRNA construct (26) that incorporates two wobble mutations to prevent self-inactivation of the viral transcript (27) and a slightly altered loop sequence (TTCGTAGC rather than TAGCTTCG) (27) . The sequence targeted is in exon 2, the first translated exon, immediately after the second in-frame Met codon. Controls were empty Banshee vector or Banshee driving expression of a scrambled shRNA insert.
LZRS retrovirus (Lz)-based construct Lz-GATA-3 was previously described (26, 28) . Other constructs were made by members of the Rothenberg laboratory as follows. Lz-G3-ENG and a related GATA-2 construct, Lz-G2-ENG, were constructed (by Sanket Acharya and Mark Zarnegar) using fusion/overlap PCR to join the first 298 aa of Drosophila engrailed protein to the DNA binding domains of GATA-2 (aa 250-437) and GATA-3 (aa 251-443) to yield products with intact engrailed N termini and intact GATA factor C termini. PCR products were cloned into pGEM-T Easy, transferred to pEF1-Myc-His A to screen for orientation, and then excised by EcoRI/XhoI digestion and cloned into Lz. Lz(estrogen receptor [ER] ) was constructed by Elizabeth-Sharon David-Fung by cloning the tamoxifen-dependent ER from STAT6-ER (provided by Naoko Arai, DNAX) (29) into Lz. Lz-GATA-3(ER) was then constructed by cloning full-length GATA-3 into Lz(ER), retaining the 5-aa linker SNSDP between the GATA-3 C terminus and the ER sequence. Lz-CRE-nerve growth factor receptor (NGFR) was constructed by Dr. Tom Taghon (Ghent University, Ghent, Belgium). Bcl-x L cDNA cloned into the MigR1 vector was purchased from Addgene (Cambridge, MA).
Retroviral infections of FLP in most experiments were carried out overnight with virus bound to plates coated with 50 mg/ml RetroNectin (TaKaRa Bio, Tokyo, Japan). Conditions were essentially as previously described (25) , except that unbound virus was not removed from the RetroNectin-coated wells prior to addition of cells and fresh media. Infections of fetal thymocytes and cells beginning T cell development by coculture with OP9-DL cells were carried out as described for individual experimental protocols.
Nucleofection
Direct nucleofection of Lin-depleted FL precursors was done using the Amaxa nucleofection system (Lonza) with a T cell kit and the X-001 program. Control small interfering RNA (siRNA; RISC-free, Dharmacon RNAi Technologies/Thermo Scientific) was transfected in parallel with a Gata-3-targeted siRNA (Dharmacon). Amaxa's pMAX GFP construct was transfected simultaneously to monitor transfection efficiency in some experiments. After transfection, cells were recovered and transferred to OP9-DL1 layers for recovery overnight, then sorted to purity using the same depletion protocol as described for derivation of FLDN cells. Adh.2C2 and RAW264.7 cells were transfected as described previously (23, 30) . GATA-3 DOSE DEPENDENCE OF EARLY T CELL DEVELOPMENT Gene expression comparison of FLDN with DN subsets from primary FT and adult thymus FLDN cells, obtained after 6 d of coculture with OP9-DL1, were sorted based on CD45, CD25, c-Kit, and CD44 for purification of total cell RNA, and equivalent DN populations were sorted by CD25, c-Kit, and CD44 expression from Lin-depleted FT (E14.5) and adult thymic DN cells in two independent biological replicates for each type of sample. cDNAs from these three types of DN1-4 populations were compared by quantitative real-time reverse transcriptase-dependent PCR (qPCR) for the genes shown in Fig.  1F and Supplemental Fig. 1 , showing levels expressed relative to b-actin.
qPCR and primers
Primer sequences, RNA preparation methods, and qPCR conditions have been reported previously (14, 20, 25, 31) . Additional primers are listed in Table I .
Single-cell cultures with Gata3 shRNA
Retrovirus-transduced FL precursors were sorted at one cell per well directly into 96-well plates preseeded with OP9-DL1 or OP9 control cells. Wells were assessed for growth by microscopy and equal numbers of wells of Gata3 shRNA-expressing and control-infected cells were harvested at 8 d and then stained for developmental markers. All remaining wells were harvested on day 12, and the additional identified expanding clones, although not included in Fig. 4A , were analyzed and included in the progression quantitation shown in Fig. 4B . Similarly, single infected ETP cells were directly sorted from wild-type or Bcl-2-transgenic mouse thymocytes into individual OP9-DL1 coculture wells and cultured either 7 (wild-type) or 9 d (Bcl-2 transgenic, not shown) prior to analysis. Descendants of singly plated cells were scored for developmental progression by tallying the stages through which each clone's descendants had passed (using a 10% frequency cutoff to determine what counts as progression). Thus, a clone in which 40% of cells are in DN1, 49% in DN2, 11% in DN3, and 0% in DN4 would be scored as having achieved progression to DN1, DN2, and DN3, but not DN4. Input cells were sorted initially as GFP + , but survival pressure on the cells frequently resulted in outgrowth of some GFP 2 cells in the colonies. Although these were also usually inhibited in progression past DN2 when the G3 shRNA was present, developmental progression scoring (e.g., Fig. 4B ) was based only on the cells remaining GFP + .
Switch cultures of DN2 cells from Gata3, Bcl11b, and Bcl11b; Gata3 homozygously floxed mice Cells were taken from mice with homozygously floxed alleles of the indicated genes or control +/+ genotypes, all crossed onto the ROSA26R-EYFP background. For experiments shown in Fig. 7 , Cre retroviral infection of Ter119-, Gr-1-, and CD19-depleted FL precursors was carried out in the presence of 5 ng/ml each Flt3L ligand (Flt3L), IL-7, and stem cell factor (SCF; c-Kit ligand). The next day, Lin 2 c-Kit
+ YFP + cells were sorted preparatively and stored in frozen aliquots at 5-6 3 10 3 cells/ vial or used to seed cultures immediately. Thus, the controls as well as the conditional deletion samples were Cre treated and validated to have expressed active Cre. In these experiments, OP9-DL4 stroma were used to support T cell development. The cells were cultured on OP9-DL4 for an initial 7-9 d with 5 ng/ml each Flt3L, SCF, and IL-7 before preparative sorting of DN2 cells. SCF was added to the primary cultures in an attempt to preserve viability of GATA-3-deficient DN1 cells by providing stronger c-Kit signaling. Some apparent violation of the DN2 block in the primary cultures of Cre + Gata3 fl/fl cells was occasionally seen in these experiments, but this was a result of the overpowering selection (Fig. 7B) for cells that had retained one undeleted Gata3 fl allele during the ETP stage, and were thus heterozygotes, as revealed in Fig. 7G . Only sorted c-Kit
2 DN2 cells from the primary cultures were transferred to secondary cultures, where 1% were moved to fresh OP9-DL4 cells and the rest were challenged by shifting to the OP9-control environment. Thus, any CD19 + cells that emerged later came from cells that had undergone at least a week of strong Notch signaling in culture and had then been sorted for a T lineage, CD19 2 phenotype. For limiting cell-number cultures of DN2 cells from the FLDN primary cultures, 25 cells/well were deposited by cell sorting into microtiter wells preseeded with OP9-control cells, then cultured with 5 ng/ml each IL-7 and Flt3L. These cultures were harvested for analysis after 2 wk. 
Pooling of multiple datasets, statistics
Means shown for RNA expression and cell numbers are geometric means, and error bars represent 1 SD from the means. Statistical significance was calculated using a two-tailed t test, and p , 0.05 was considered significant. Alternatively, for sample sets with low n and non-normal distributions, the Mann-Whitney-Wilcoxon U test (two-tailed) was used to calculate p, using the Web site http://elegans.som.vcu.edu/∼leon/stats/ utest.html. f/f cells (same genetic background but without deletion). Libraries for RNA-seq analysis were generated by the Jacobs Genetics and Genomics Center at the California Institute of Technology essentially as described previously (13) with minor modifications, using NEBNext multiplex reagents (New England Biolabs) and determining single-end sequences on an Illumina HiSeq 2500 high-throughput sequencer. Raw sequence reads as fastq files were processed using TopHat (v2.0.6) to map to the mm9 mouse genome assembly, using Cufflinks (v2.1.1) to generate BAM files, bamToBed to generate BED files (BedTools v2.14.2), and then BedTools genomecov to generate bedgraph files that were normalized by the total number of mapped reads (RPM). For visualization in the University of California Santa Cruz genome browser (http://genome.ucsc.edu), we converted the bedgraphs to BigWig files. Data were deposited in Gene Expression Omnibus (accession no. GSE59215) (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE59215).
RNA-seq analysis
Differential expression analysis was carried out as follows. First, results were filtered to remove small gene models (Snor, Mir, Rpl, and Rps) and genes with low expression values (less than five fragments per kb of exon per million fragments mapped [fpkm]). Then the remaining values (9580 gene models) were log 2 transformed (floor of 0.01), and a Pearson correlation matrix was computed for the four datasets. All four datasets crosscorrelated with r $ 0.9. The developmental staging of the samples was assessed by using an index set of 173 developmentally regulated genes annotated as transcription regulators from our RNA expression data reported previously for wild-type FLDN cells and adult thymocytes (13) . Values for these index genes in each experimental sample were compared with the values in our reference samples using principal component analysis. This analysis verified that the samples fall into the DN2a-DN2b interval as expected by differentiation time and surface phenotype. Then, two statistical approaches were applied to identify new candidates for particularly GATA-3-sensitive target genes. Cuffdiff (32) was used to identify differentially expressed genes in the two comparisons pooled together, and those with p values of ,0.01 were considered significant. In parallel, genes with substantial differential expression within each pair were identified by rank product and reverse rank product in the two comparisons pooled together (downregulated and upregulated genes), with p values for the replicate comparisons calculated based on minimizing rank product/rank sum (p , 0.005) (33) . Additional differential expression criteria were used for transcription factor genes as described in the text. The early time point chosen and the dynamic developmental context meant that only strongly and rapidly affected genes could be detected above background. However, this survey of limited statistical power was designed as a search tool to identify new candidates for rapidly GATA-3-sensitive genes that could be tested for validation in additional experiments, that is, the GATA-3 knockdown or deletion tests assayed by qPCR in independent experiments as presented in the text.
Results

Expression pattern of GATA-3 in T development
Gata3 is expressed in multipotent prethymic precursors for T development (Lin 2 c-Kit hi Sca-1 hi CD27 + FL or bone marrow cells) (34) . However, much higher Gata3 expression is seen even in the most immature cells within the thymus (35) , with only a little further increase (∼3-fold) in Gata3 RNA during T lineage commitment (11, 13, 28, 31, 36) . However, GATA-3 protein levels can be regulated by posttranscriptional mechanisms as well (37) (38) (39) (40) (41) . We therefore measured GATA-3 protein content by direct intracellular staining in each of the early DN stages ( Fig. 1A ; top panels show gating strategy).
In adult B6 mice, GATA-3 protein is initially low in the c-Kit hi CD44 + CD25 2 (early T cell precursor) population, the subset of CD44 + CD25 2 DN1 thymocytes that includes T cell precursor activity. GATA-3 levels barely change as the cells initiate expression of CD25 (DN1 25 lo ), but rise $3-fold as they turn on CD25 to become DN2a (c-Kit hi CD44 + CD25 + ) (Fig. 1A, middle) . Dissecting the DN2 stage by c-Kit expression levels to separate uncommitted from committed cells (42) , the DN2b (c-Kit lower) newly committed cells have the highest levels of GATA-3 protein and RNA (Fig. 1A + (double-positive, DP) stage (26) . RNA levels, similar to protein levels, rise slightly in the DN2 and DN3 stages (Fig. 1B) . This pattern is seen also in both Rag2 2/2 adult thymocytes and normal B6 fetal thymocytes, confirming that the increase does not depend on TCR gene rearrangement (Fig. 1C) . These results agree well with the expression reported for Gata3 knock-in alleles (3, 7, 11) .
GATA-3 follows a similar pattern during T cell differentiation in vitro when c-Kit + CD27 + Lin 2 precursors from E13.5 FL are cultured on OP9-DL1 stroma to generate DN pro-T cells (Fig. 1D,  1E ). As shown by detailed expression comparisons of .55 genes in Supplemental Fig. 1 (for primers, see (Fig. 1B, 1F ) and a slightly accelerated GATA-3 protein increase relative to adult thymocytes, peaking at DN2a and DN2b, then subsiding slightly from DN2b to DN3 (Fig. 1C, D) . In all three sources of developing T cells, the timing of peak GATA-3 expression at DN2 suggests a role between thymic entry or initiation of T cell development and commitment.
Reduction of GATA-3 inhibits viability and population expansion
To test the effect of acutely downregulating GATA-3, we used Banshee G3-3W ( Fig. 2A) , a bicistronic retroviral shRNA expression construct with a GFP marker designed to block translation from Gata3 transcripts specifically (26, 27) . The magnitude, speed, and stability of knockdown using this construct were assayed by intracellular GATA-3 staining in the DN3-like Adh.2C2 cell line (23), with Raw264 myeloid cells, which do not express GATA-3, used as a specificity control (Fig. 2B ). Retroviral expression of Gata3-specific shRNA reduced GATA-3 protein to ∼50% within 20 h, stabilizing at ∼45% of control levels for at least 6 d (Fig. 2C, 2D ). Similarly, FLDN cells cultured for 6 d after infection with Gata3 shRNA had GATA-3 protein levels reduced to ∼50% of control in cells with DN2 and DN3 phenotypes and reduced to isotype control background levels in cells retaining a DN1 phenotype (Fig. 2E ). For more extensive confirmation of the effects of this shRNA on Gata3 RNA and GATA-3 protein in the Adh.2C2 system, also see our recent report (43) . Gata3 shRNA thus consistently lowered GATA-3 protein levels, despite its generally mild effect on RNA levels. Even this modest reduction in protein expression had pronounced functional consequences. Six days after infection, Banshee G3-3W-infected Adh.2C2 cells were profoundly inhibited in proliferation, viability, and the ability to sustain vector GFP expression as compared with cells infected with control virus, implying that cells with most severe GATA-3 loss were being eliminated (Fig. 2F, 2G , top panels). When FLPs were infected with G3-3W and cultured with OP9-DL1 stroma (T cell conditions), a steep, progressive loss of virus-transduced GFP + cells was seen after 48 h ( Fig. 2G , middle; note time scale; also see Supplemental Fig. 2D ). However, when the same precursors were cultured on OP9-control to promote B and myeloid development, the percentage of GFP + cells continued to increase ( Fig. 2G , lower; see Supplemental Fig. 2D ). Thus, the effects of Gata3-specific shRNA expression faithfully reflect the T lineage-specific requirement for GATA-3.
The strength of these effects was surprising because no evident phenotype had been reported after Cre treatment of a simple Gata3 fl/+ heterozygote. We also failed to detect substantial alterations in FLDN cell development in vitro from Gata3 fl/+ ; ROSA26R-EYFP cells that were transduced with Cre retrovirus and sorted for Cre-induced EYFP expression (Supplemental Fig.  2A ). The normal cell surface phenotypes of these Gata3 heterozygous cells were validated by their normal expression of a panel of developmentally regulated genes in the cells (Supplemental and the RNA-seq data presented later). Thus, the shRNA reduces GATA-3 expression more than the heterozygous deletion.
Reduced GATA-3 levels impair the DN2/DN3 transition
Reduced GATA-3 protein levels caused a stage-specific developmental block as well as reduced proliferation, as shown for sorted populations of Banshee G3-3W-transduced GFP + FL precursors after 3-4 d of differentiation on OP9-DL1 (Fig. 3A, 3B , left panels). Direct nucleofection of a commercial anti-GATA-3 siRNA into such precursors gave similar results (Fig. 3A , right panels, siRNA). In both cases, the control cells were transitioning to DN3 stage at harvest, but the GATA-3 knockdown samples were blocked with a DN2 phenotype (Fig. 3A) . A similar phenotype using this shRNA was also recently seen by Kee and colleagues (44) .
The observed block was consistent with two possibilities. First, GATA-3 might need to act during DN2 stage to drive progression to DN3. Second, because of earlier roles of GATA-3 (7), the knockdown cells might simply be delayed in development. To distinguish between these possibilities, we allowed FL-derived precursors to develop normally to DN1, DN2, and DN3 stages in vitro, and only then transduced them overnight with control or Gata3 shRNA-expressing retrovirus. Each infected subset was then sorted and returned to culture for further differentiation (Fig. 3C ). FL-derived DN1 cells transduced with Gata3 shRNA halted at DN2 stage in OP9-DL1 culture (Fig. 3C, FLDN1) , and catastrophic failure of cell expansion accompanied this block (Fig. 3B, right) . Even after cells had already developed to the DN2 stage, GATA-3 reduction delayed progression to DN3 (Fig. 3C, FLDN2 ) and often blocked it altogether (three of six experiments, not shown), implying that the DN2-DN3 transition was specifically vulnerable to loss of GATA-3. Notably, although decreased GATA-3 substantially inhibited FLDN1 and FLDN3 population expansion, the FLDN2 population was more resistant (Fig. 3B) .
Loss of GATA-3 from FL-derived DN3 cells caused a delay in progression to the DP stage as well as severe loss of cellularity, as reported for conditional Gata3 knockouts with Lck-Cre in vivo (10) (Fig. 3C, FLDN3 ). However, surviving cells from some of these GATA-3 knockdown samples displayed a "retrograde" CD44 + DN2-like phenotype (50% of DN3 knockdown experiments, data not shown). Thus, at a minimum, survival in the DN3 stage appears less tolerant of reduced levels of GATA-3 than in the DN2 stage. E14-14.5 fetal thymocytes develop more rapidly than do FLDN cells in OP9-DL1 culture and pass more efficiently through DN2 to DN3 (Fig. 3D, 3E ). By day 6.5, ∼50% of control vector-transduced fetal thymocytes had acquired CD4 and/or CD8. However, when transduced with G3-3W, the great majority of fetal thymic DN1/ ETP cells were blocked at DN2 at both early (3.5 d; Fig. 3D , top) and late (6.5 d; Fig. 3E, top) time points. Thus, the DN2 block is robust under both fast and slow development kinetics.
The DN2 stage block caused by GATA-3 knockdown is separable from growth inhibition Severe cell loss raised the possibility that the DN2-DN3 developmental block might simply reflect apoptosis at DN3. To test whether viable cells are developmentally blocked, we knocked down expression of GATA-3 in Bcl-2-transgenic fetal thymic ETP cells. Bcl-2-transgenic E14-14.5 ETP cells survived ∼3-fold better than did wild-type cells after knockdown of GATA-3, yet these cells went on to be as severely DN2 arrested as did comparison of sorted thymic T cell precursors with in vitro-generated FLDN subsets. Early DN thymocyte subsets from adult and fetal murine thymus were depleted of mature T and non-T lineage markers by magnetic bead binding and column selection and sorted into DN1-DN4 subsets. Two independent biological samples of each series were generated for this analysis. Adult thymus (AT) samples were composed of two adult mouse thymi per sorted biological sample. FT was obtained from E14/E14.5 fetuses from timed mated B6 mice. FLDN cells were OP9-DL1 cultured cells generated from c-Kit
+ E13.5/E14 FL precursors cultured on OP9-DL1 for 6 d, then sorted as shown into pure DN1, DN2, DN3, and DN4 developmental populations for analysis. Red/pink bars indicate the two sets of fetal thymic DN1-DN4; green bars, FLDN1-FLDN4; and blue bars indicate adult thymic DN1-DN4. 
Primers described as "alternate" are new primers (used in Fig. 5B ) for genes that we have measured in other experiments using other previously reported primers.
a Same as described in Li et al. (20) . their nontransgenic counterparts (Fig, 3D , lower panels, and data not shown). Even when the Bcl-2-transgenic fetal thymic ETP cells were cultured 6.5 d, Gata3 shRNA-expressing ETP cells remained blocked at DN2, whereas control cells reached the DP stage (Fig. 3E, lower) . Thus, the loss of the viability-promoting role of GATA-3 is not the sole cause for the observed arrest at DN2.
Clonal analysis of differentiation from single-cell precursors provided additional evidence that reduced GATA-3 could inhibit developmental progression separately from its role in survival and proliferation. Individual FL precursors infected with a control vector, sorted as GFP + onto OP9-DL1 layers in 96-well plates, generated a range of descendants spanning all the early stages of T development after 8-12 d (Fig. 4A, top) . The clonal descendants of Gata3 shRNA-expressing FL precursors, in contrast, again were unable to progress beyond DN2 (Fig. 4A, lower) . We quantified developmental progression by assuming that cells pass through DN1, DN2, DN3, and DN4 in order, and scored individual clones as "positive" for every stage that had been passed through by at least 10% of the cells in the clone at the time of analysis (see Materials and Methods). Using this scale to score progression in each clone, the developmental distributions of the control and GATA-3 knockdown clones are shown (Fig. 4B, left) . No significant progression beyond DN2 was seen in any clones that grew from Gata3 shRNA-transduced FL precursors (only 1 of 17 had .1% DN3 cells). In contrast, .40% of empty vectortransduced clones had reached DN3 or beyond (Fig. 4A , top, 4B and data not shown). Importantly, the Gata3 shRNA-expressing clones could not surmount the DN2 block even in the cases where individual precursors had generated cell numbers comparable to controls (Fig. 4B, right) . DN2 arrest was also observed with sorted single fetal thymocyte ETP cells expressing Gata3 shRNA (Fig. 4C, left) , and these ETP clones showed reduced expansion, consistent with behavior in bulk cultures (Fig. 4C, right and data not shown) . Thus, T cell precursors with reduced GATA-3 levels are intrinsically inhibited from developmental progression to DN3.
GATA-3 conditional knockout confirms a requirement for GATA-3 for DN2-DN3 transition
To exclude off-target shRNA responses (45) as the cause of the DN2-DN3 block, we also tested the early GATA-3 role by inducing conditional deletion of the gene in vitro, infecting Gata3 fl/fl FLPs (10) with a Cre-expressing retrovirus before initiating T cell differentiation. More severe effects were expected in cells with complete loss of Gata3 than with shRNA-induced dosage reduction (7, 11) , but the question was whether any cells that did reach DN2 would be able to proceed to DN3. To minimize the number of cells in which Gata3 could escape deletion, we sorted all cells for Cre vector expression after initial culture period on OP9-control stroma, and only then was T development triggered by transfer to OP9-DL1. As positive controls for Cre activity, cells from Gata3 +/+ ROSA26R-EYFP fetal mice were transduced in parallel (Fig. 4D) . Cre treatment of cells with a floxed Gata3 allele showed that as with shRNA, development was blocked at DN2 (Fig. 4E) , whereas Cre-treated control precursors progressed to DN4. Thus, this deletion model also demonstrated that GATA-3 was needed for transit from DN2 to DN3.
GATA-3 reduction causes derangement of the DN2-DN3 transitional program
The DN2-DN3 transition is defined not only by downregulation of CD44 but also by downregulation of c-Kit and, intracellularly, the downregulation of PU.1. Despite the strong effect on DN2-DN3 progression seen by criterion of CD44 expression, the G3-3W shRNA-treated cells continued to downregulate c-Kit expression almost similar to controls, implying that CD44 and c-Kit regulation had become divergent (Fig. 5A) . The Gata3 shRNA-transduced cells also appeared to increase their CD25 levels as a consequence of increased average cell size (data not shown), unlike normally progressing pro-T cells, which shrink on entering DN3a stage. This implied a more substantial defect in regulation of the DN2-DN3 program as a whole when GATA-3 levels are reduced.
The discordant c-Kit and CD44 levels raised the question whether the cells are intrinsically more similar to c-Kit lo DN2 cells or CD44 hi DN3 cells. To resolve this, we transduced Bcl2-transgenic FLPs with G3-3W or scrambled shRNA, cultured them for a week on OP9-DL1, and then sorted DN1, DN2a, and DN2b subsets of the transduced GFP + cells based on their c-Kit levels. Despite the presumed G3-3W effect on the protein levels of GATA-3, little effect on Gata3 RNA was seen. However, the G3-3W-transduced cells that had reached DN1, DN2a, and DN2b-like phenotypic categories exhibited pronounced and specific gene expression abnormalities. Their elevated Spi1 (PU.1) and Bcl11a and reduced Bcl11b and Ets1 transcripts, in comparison with scrambled shRNAtransduced controls, implied an early DN2 arrest state. However, at the same time they also showed experimentally variable, precocious expression of the Notch-dependent DN2b-DN3-specific HEBalt transcript (an alternative promoter isoform of Tcf12) and the DN3-specific SpiB transcript (Fig. 5B, 5C ).
Gene expression tests at earlier time points confirmed changes in gene expression that were discordant with normal developmental patterns as well (Fig. 5C, 5D ). At 60 (Fig. 5C ) or 40 h (Fig. 5D ) after transduction with GATA-3 shRNA, PU.1 (Spi1) expression was repeatedly found slightly elevated in GATA-3 knockdown cells as compared with controls. At these earlier time points as well, SpiB and often HEBalt were found to be upregulated. The large experiment shown in Fig. 5C was carried out to measure short-term effects of GATA-3 knockdown on cells that were in precisely defined developmental stages before shRNA treatment, with RNA analysis then performed on progeny populations re-sorted as DN1, DN2, or DN3 after 60 h of further culture. The three experiments summarized in Fig. 5D tested earlier responses to transduction with G3-3W in primary E15.5 fetal thymocytes from Bcl2-transgenic mice. A consistent finding among the panel of developmentally significant genes measured was that Spi1 levels were elevated relative to controls as early as 2 d after transduction (Fig. 5B-D) , whereas onset of Bcl11b expression from ETP/DN1 precursors to DN2 was also dampened, although not maintenance of Bcl11b once already activated in late DN2 stage (Fig. 5B, 5C ).
HEBalt depends on Notch signaling and HEB/E2A (46) , so that the HEBalt upregulation seen in several short-term experiments ( Fig. 5C and data not shown) implies that these crucial T cell regulatory inputs persist despite GATA-3 reduction (11). The normal or increased expression of Notch target genes CD25 (Il2ra) (Fig. 5B) , HEBalt (Fig. 5C, 5D ), and Dtx1 (Fig. 5D ) in Gata3-deficient cells also implies that Notch signaling con- tinues, independent of GATA-3 activity levels. At the same time, the split DN2/DN3 phenotype of GATA-3 knockdown cells is a mirror image of our previous finding that when Gata3 is overexpressed in fetal thymocytes, c-Kit is upregulated and PU.1 is downregulated (Ref. 14 and Supplemental Figs. 2E,  Fig. 3G ). GATA-3 is epistatic to PU.1 in regulating DN2-DN3 progression PU.1 and GATA-3 act as antagonists in a network circuit in which GATA-3 restrains the ability of PU.1 to cause myeloid differentiation of DN pro-T cells, even when Spi1 itself is exogenously expressed and not under GATA-3 control (43). PU.1 protein naturally begins at high levels in ETP and DN2a cells, but falls immediately after GATA-3 reaches its peak (data not shown) (42) , and our results suggested that GATA-3 might be required for this decline. CD44 that defines the DN2 arrest also appears to be positively regulated by PU.1 (A. Champhekar, unpublished results). To test whether sustained PU.1 expression is the cause of the DN2-DN3 abnormality that occurs when GATA-3 levels are reduced, we asked whether deletion of PU.1 would restore normal development of GATA-3 knockdown FL precursors. Taking FL precursors from Spi1 fl/fl mice and B6 controls, we treated them in parallel with retroviral Cre to delete PU.1 from the mutant precursors and placed them in T cell differentiation culture for 5 d. Then PU.1-deficient and control cultures were harvested, infected with G3-3W or empty vector, sorted to isolate transduced ETP cells, and these were returned to culture for 7 d more. Fig. 5E shows that loss of PU.1 indeed accelerated the progression from ETP to DN3 in cells with normal levels of GATA-3. However, knocking down GATA-3 still blocked development at DN2, with or without an intact Spi1 gene. Therefore, the need for GATA-3 to promote DN2-DN3 progression involves additional target genes besides PU.1.
Acute deletion of Gata3 reveals additional GATA-3-sensitive targets
Overall, the relatively modest gene expression effects seen at early time points raised the concern that shRNA-mediated inhibition could be too slow, quantitatively mild, or asynchronous to detect the whole first tier of GATA-3 regulatory targets. For closer study of early responses to GATA-3 deprivation, we therefore used retroviral Cre transduction of cells from homozygous Gata3 fl/fl ; ROSA26R-YFP mice and sorted the YFP + DN1, DN2a, and DN2b cells for analysis within 18 6 2 h, before viability or proliferationbased selection could skew the population (Fig. 6A) . These cells were compared with empty vector-infected cells or Cre-treated YFP + cells from Gata3
;ROSA26R-EYFP mice as controls. The level of Gata3 RNA from the intact floxed gene was reduced by .10-fold by Cre treatment, as determined by exons 3-4-specific qPCR (Fig. 6B) . In these cells, within the first day, again Spi1 (PU.1) was upregulated. However, in contrast to cells transduced with Gata3 shRNA, now Zfpm1 (FOG1) was clearly downregulated. This was significant because Zfpm1 exhibits strong binding of GATA-3 in vivo (13) and seems responsive to GATA-3 in a model cell line system (43) . When incubation was continued for an additional day before harvesting the cells, detectable reductions in Tcf7, Rag1, Kit, and Zbtb16 (PLZF) were seen, as well as effects on Bcl11b and Ets1 (Fig. 6B) . These effects suggest that such targets associated with particularly strong binding of GATA-3 in vivo (13) may require .2-to 3-fold reductions of GATA-3 activity before their expression is affected.r
Global analysis of GATA-3-dependent genes in DN2 cells by RNA-seq
These results suggested that additional immediate targets of Gata3 in thymocytes undergoing commitment might be found in a whole-genome screen using the acute deletion strategy. We therefore carried out exploratory genome-wide analyses of control and acutely Gata3-deleted DN2 cells using RNA-seq. The Cre-transduced FLDN2 cells from Gata3 fl/fl ;ROSA26R-EYFP + mice were sorted ∼18 h after transduction in two independent experiments, compared in each case with a different control that had been cultured in parallel: in one, Cre-treated cells from B6 mice (wild-type Gata3), and in the other, vector marker-positive cells from Gata3 fl/fl ;ROSA26R-EYFP mice transduced with an empty vector. At this very early time point, there were no detectable differences yet in viability, cell number, or phenotype between the Gata3-deleted and control cells in either experiment (data not shown), but sequences from Gata3 exons 4 and 5 were effectively eliminated from the transcript repertoire of the Cre + Gata3 f/f cells (Fig. 6C ). Transcriptome analyses were carried out using high-throughput sequencing, and gene expression was mapped and quantitated using TopHat and Cufflinks software.
The data were monitored first to establish the global developmental stages that each sample best represented. Catching the cells at identical points even in a normal developmental trajectory is difficult in independent experiments. Overall, the expression patterns agreed well across the four samples (9580 transcripts scored), with Pearson's r values of 0.90-0.96 between all pairwise comparisons. To gain a finer mapping of the cells' developmental positions, we established a reference list of 173 developmentally regulated transcription factors from our previous analysis of wildtype cells (13) to create a high-dimensional metric of any sample's advancement through the commitment process. The expression levels of these genes were then used for principal component analysis (Fig. 6D , Supplemental Table IA) their respective controls, but displaced from the normal trajectory, in parallel. This was consistent with the interpretation that the effects of Gata3 deletion are not simply a developmental block or acceleration of the normal program, but a deviation from it.
To locate candidates for new GATA-3-sensitive genes, we ranked the genes with greatest differences between controls and experimental samples in both experiments, using both rank product and Cuffdiff analyses with a cutoff to exclude genes expressed at very low levels, as described in Materials and Methods (Supplemental Table IB-D) . In general, at the time point analyzed (∼18 h of Cre exposure), most expression differences were still small, limiting statistical power. However, the limited comparison still revealed ∼100 genes of most interest (Supplemental Table IC) , and fold changes in expression values in the two comparisons for the top scoring genes are shown in Fig. 6E . Although genes detected as differentially regulated by qPCR (compare Fig. 5B-D and Fig. 6B ) also behaved consistently in this RNA-seq analysis (e.g., Ets1, Bcl11b, Zbtb16, Rag1), most did not show the strongest effects statistically. However, Spi1 (PU.1), SpiB, and Bcl11a were found among the most upregulated in these Gata3-deficient DN2 cells (Fig. 6E) , supporting the interpretation that these are directly or indirectly repressed in normal DN2 cells by GATA-3.
The top candidates for GATA-3 + regulatory targets included genes known to play roles in Th2 cell development, innate lymphocyte type 2 (ILC2) development, and allergic disease, albeit not previously known to be involved in early pro-T cell specification. A highly GATA-3-dependent gene, Cpa3, had previously been shown to be upregulated when fetal thymocytes overexpressed GATA-3 (14) . These comparisons showed strong effects also on Il9r, Il17rb (IL-25R component), Fgf3, Tnfrsf9 (4-1BB, CD137), Cyp11a1, and germline transcripts of the TCRg C1 cluster. Il9r, Il17rb, Tnfrsf9, Pdcd1, and Cyp11a1 are also genes recently shown to be positively regulated by GATA-3 in ILC2 and/or Th2 cells (12, 47, 48) , as well as Il17rb, Pdcd1, and Ms4a4b in ILC3 or Th17 cells (12, 47) . In contrast, the genes appearing as negative regulation targets in our cells do not generally appear GATA-3 regulated in Th2 or ILC2 cells (with the exception of Lair1), mostly because they are completely silent in those developmental contexts. Although not all of the genes affected in our analysis are necessarily direct targets (see Discussion), they reveal some commonalities in GATA-3 targets between early pro-T cells and peripheral Th2 and ILC2 cells (47) (48) (49) .
GATA-3 as a positive and negative regulator of other developmental regulatory factors
Because genes of most interest to explain developmental changes prominently include those encoding transcription factors, we specifically examined the impacts of Gata3 deletion on a genome-wide list of transcriptional regulatory genes (Supplemental Table IE, 1F) . From a master list of 1640 regulators (Supplemental Table IF , list 1), 973 were expressed highly enough to evaluate (Supplemental Table IF , lists 2 and 3) . To accommodate the variation in starting developmental states in the two comparisons, we used two scoring systems to identify genes of interest (Supplemental Table IE ) based on consistency of the Gata3 deletion effect, minimum fold change, agreement between the controls, and overall strength of expression so as to minimize measurement noise. One list was identified using slightly less stringent criteria but adding a requirement for Cuffdiff p of ,0.1 (Supplemental Table IE , list 1), and the other was identified using more stringent categorical criteria irrespective of the Cuffdiff p value (Supplemental Table IE , list 3) . In both lists, Ets1 was scored as a positive target whereas SpiB and Spi1 were scored as negative regulatory targets. Bcl11b also crossed the threshold as a positive target in one list, and Bcl11a did the same as a negative target. This screen also identified Pou2f1 (Oct1), Hmbox1, Anks1, and Hmga2 as positive regulatory targets of GATA-3 and Cbx8 and Bc13 as additional negative targets. Note that Zfpm1, Tcf7, and Myb, also genes with strong GATA-3 binding in vivo, showed weaker but repeated changes consistent with being functionally positive regulatory targets even though they did not rise to the top statistically (Supplemental Table IE , list 2).
The significance of effects on Pou2f1, Hmbox1, Anks1, and Hmga2 are difficult to evaluate because so little is known about their roles in T cell development. However, the evidence that Bcl11b and Ets1 depend on GATA-3 activity to be induced raises the possibility that these mediate GATA-3 roles in T cell lineage commitment as well as differentiation.
GATA-3 suppresses B cell potential: a commitment role distinct from that of Bcl11b
Full commitment as well as progression from DN2 to DN3 are known to depend on Bcl11b, the regulatory gene that is most dramatically activated between DN1 and DN2b in normal cells (20, 50) . If GATA-3 mediates commitment effects through induction of Bcl11b, then Bcl11b knockouts should recapitulate some of those effects in a GATA-3 + context (11) . However, the effects of Bcl11b and GATA-3 on early pro-T cells are not the same in general. Unlike Gata3-deleted cells, Bcl11b knockout cells are highly viable. They upregulate c-Kit rather than downregulating it, and even after weeks of OP9-DL1 culture remain proliferative, yet are still able to generate NK and myeloid cells when shifted to OP9-control stroma (20) . We therefore tested whether the specific roles of GATA-3 and Bcl11b in commitment are the same. The results of this series of experiments with FL and bone marrow precursorderived DN cells are reported in full in Tables II and III. To characterize the genetic interactions between GATA-3 and Bcl11b, we generated doubly floxed Bcl11b Table 1A ). The axes for the principal component analysis were calculated from the expression levels of these factors in samples described in Zhang et al. (13) . Overall, the experimental samples are situated between normal FLDN2a and FLDN2b, consistent with the phenotypes and lengths of culture, but the two experiments are not identical. (E) Highest scoring genes affected within 20 h by deletion of Gata3 in two experiments: genes downregulated by loss of Gata3 are at lower left; genes upregulated by loss of Gata3 are at upper right. Graph shows fold changes in expression relative to controls on log 2 scale with effects seen in comparison 1 on the x-axis and effects seen in comparison 2 on the y-axis. Genes indicated in black are clearly expressed. Names of other genes fulfilling statistical criteria but expressed at very low levels are indicated in gray.
on their activation of YFP (Fig. 7A) , seeded on OP9-DL4 stroma, and compared for subsequent development (Fig. 7C, 7D , Supplemental Fig. 3 , and data not shown). With or without Bcl11b, GATA-3 loss caused a severe relative reduction in cell yield (Fig. 7B) , and downregulation of c-Kit, with an increased expression of CD25, in contrast to the effects seen when Bcl11b is deleted alone (Fig. 7B-D,  Supplemental Fig. 3G , and data not shown). In all these populations lacking a Bcl2 transgene, cells surviving the 7-8 d preculture were biased toward preservation of at least one intact Gata3 allele (Fig.  7F) , and this made the DN2 arrest appear incomplete. However, when DN2 cells were sorted from the Cre-treated cells of all four genotypes (Fig. 7C) and then transferred to OP9-control stroma, they displayed sharply different developmental potentials (Fig. 7D , Supplemental Fig. 3A-D) . All genotypes generated NK-like cells consistently (Supplemental Fig. 3A -D, cells staining with NK1.1 plus DX5). However, a new phenotype also emerged from the DN2 cells of genotypes with deleted Gata3: profuse blooms of CD19 + , CD45 int B lineage cells (Fig. 7D, 7E, Supplemental Fig. 3H ). The cells with a B cell surface phenotype strongly expressed B lineage transcription factors Ebf1 and Pax5 and had substantially downregulated T cell genes such as Thy1, Tcf7, and TCRb germline transcripts (Supplemental Fig. 3I ). However, in contrast to normal B cells, these cells expressed TCRg and TCRd transcripts, consistent with their early T lineage origin (Supplemental Fig. 3I ). Generation of B cells from such OP9-DL4-cultured, sorted DN2 pro-T cells was never observed with wild-type cells and was barely detectable in any experiments with Bcl11b single knockout cells (Table II) .
B cells were generated in secondary culture from Cre-treated DN2 cells with a floxed Gata3 allele, with or without floxed Bcl11b, in seven of seven experiments (Tables II, III) . However, this was not a uniform trait within the Cre-treated Gata3 fl/fl DN2 populations. In microtiter cultures seeded with limiting numbers of sorted ROSA26R-EYFP + DN2 precursors of different genotypes, no B cells emerged from B6 control or Bcl11b single-knockout cells (Supplemental Fig. 3A, 3B) . B cells did emerge from Gata3 singleknockout or Gata3, Bcl11b double-knockout cells, but only from a minority of these limiting dilution cultures (Supplemental Fig. 3C,  3D ). The colonies containing B cells proliferated strongly, outstripping those with NK cells only (Fig. 7E, red dots versus blue dots) .
One explanation for why B cell clones emerged rarely could be that survival pressures caused many Cre + DN2 cells to retain a Gata3 allele. This proved to be true based on real-time PCR assays that quantitated deleted versus intact (floxed) Gata3 alleles (Fig. 7F, 7G) . Not only the starting populations, but also all "GATA-3 knockout" colonies that grew on OP9-DL4 stroma actually retained one floxed, undeleted Gata3 allele. Of the colonies that grew on OP9-control, those of NK cells (Fig. 7F , blue symbols) also all retained Gata3. The only colonies that had deleted both copies of Gata3 were the ones that generated B cells (Fig. 7F, red symbols) . In contrast, both NK and B cell colonies showed equal, complete deletion of Bcl11b when these alleles were floxed (Fig. 7I, 7H ). Thus, only by loss of all Gata3, irrespective of the presence or absence of Bcl11b, could DN2 pro-T cells convert into B cells.
Deletion of Gata3 at DN2 stage can restore B cell potential
To determine whether GATA-3 itself is needed continuously to suppress B cell potential, we allowed cells to develop to the DN2 stage with Gata3 intact and then induced deletion with a tamoxifen-inducible Cre-ERT2 transgene. Bone marrow cells from these mice were cultured on OP9-DL4 to the DN2 pro-T cell stage, then treated with tamoxifen, and DN2 cells were purified by sorting (Fig. 8A, 8B ). They were then tested for B cell potential by transfer to OP9-control cultures. Short-term activation of Cre-ERT2 did not cause disappearance of the DN3 cells already generated but changed the potential of the DN2 cells. Again, no B cells developed from control Cre-treated DN2 cells, but B cells consistently grew out from the Cre-treated Gata3 fl/fl precursors, even though they had harbored an intact Gata3 gene until the DN2 stage (Fig. 8C) .
Despite the strong outgrowth of converted B cells, the B cell precursor frequency within the Gata3 fl/fl Cre-treated DN2 population was low. Real potential might be masked by the harsh T lineage effects of acute Notch signal deprivation plus the sudden loss of GATA-3, in transition before the cells switch fates. To obtain a clearer estimate of B cell potential, we generated DN2/3 cells from Gata3 fl/fl Cre-ERT2 and control Cre-ERT2 mouse bone marrow Lin 2 c-Kit + Sca1 + cells (Fig. 8D, 8E ), then infected them with Bcl-x L or control retroviral vectors (Fig. 8F) , and only then treated them overnight with tamoxifen to activate the Cre. The transduced cells were then sorted and transferred to B cell conditions at limiting dilution for 14 d. As shown in Fig. 8G , imposed expression of Bcl-x L enhanced the detection of B cell precursors in the Gata3-deleted population by 5-to 10-fold without unmasking any B cell potential in the controls. Once GATA-3 is induced, therefore, its vital role in survival amplifies its effectiveness as a suppressor of alternative fates.
Dose-dependent effects of GATA-3 on B and myeloid developmental choice
The difference between full GATA-3 expression and GATA-3 dosage reduction can directly contribute to myeloid potential through the GATA-3 sensitivity of PU.1 expression (Figs. 5, 6A ) and PU.1 function (43) (data not shown). Although Gata3 deletion also unmasks B cell potential as late as the DN2 stage (Figs. 7, 8) , B cell development was never seen from G3-3W-treated DN pro-T cells, and the experiments shown in Figs. 5 and 6 revealed no significant activation of Ebf1 or Pax5 when GATA-3 activity was merely reduced (data not shown). We therefore considered that B cell potential might be particularly easily repressed by low doses of GATA-3. Indeed, FL precursors in which GATA-3 was reduced by either shRNA or siRNA (Fig. 9A, 9B ) often generated an absolutely enhanced yield of B lineage cells (CD19 + ) under B cell/myeloid conditions in OP9 control cultures (in 7 of 10 experiments) (Fig. 9C) . Conversely, GATA-3 overexpressing FL precursors, even when Bcl2 transgenic, generated dramatically reduced numbers of CD19 + and CD11b + cells in B cell/myeloid conditions (Fig. 9A, Gata-3 ). To test whether GATA-3 may act as a direct repressor of genes that promote B cell fate, we designed a construct that fuses GATA-3 to the repression domain of Drosophila engrailed to create an obligate repressor with GATA factor DNA binding specificity. This construct indeed dampens c-Kit expression in early pro-T cells, consistent with the previous evidence that this gene can be positively regulated by GATA-3 (14) (Supplemental Fig. 2E ). Gata-3 engrailed mimicked wild-type GATA-3 expression, however, as it inhibited B cell development (Gata-3 engrailed; Fig. 9A, Supplemental Fig. 2D ) . This effect was particularly striking because Gata-3 engrailed was far less antagonistic to myeloid development from the FL precursors than wild-type GATA-3, implying a sharp difference in the crucial target genes for these two developmental restriction effects (Fig. 9A, right panels) .
To test systematically how GATA-3 dose might affect developmental alternatives, we generated a retroviral GATA-3 construct fused through a linker to an estrogen receptor hormone binding domain [GATA-3(ER)]. This construct offers two levels of dose control, the first through downregulation of vector transcription that occurs in some cells (28) , and the second through titrated tamoxifen control of nuclear localization of the expressed fusion protein. We transduced FL precursors with this construct, sorted GFP + transductants, then cultured them under B cell-and myeloidpermissive conditions, with and without tamoxifen. With tamoxifen, GATA-3(ER) blocked GFP hi cells from both B and myeloid fates ( Fig. 9D and data not shown) , especially M-CSF-R + (CD115 + ) and F4/80 + macrophages (data not shown). However, generation of CD19 + B cells was clearly most sensitive. B cell generation could be inhibited by strong expression of GATA-3(ER) even without tamoxifen (Fig. 9D , GFP hi , and data not shown) through the small fraction of GATA-3 that still leaks to the nucleus in these conditions (A.M. Arias, unpublished data). In this case, myeloid differentiation (CD115 + ) was clearly less affected (Fig. 9D , arrows, and data not shown). GFP lo cells that had downregulated the GATA-3(ER) construct showed a parallel response pattern at higher doses of tamoxifen (relative sparing of myeloid cells: arrows in Fig. 9D , GFP hi versus GFP lo ). Thus, as summarized in Fig. 9E , distinct dose thresholds for GATA-3 not only control DN2-DN3 progression but also limit distinct alternatives to T cell fate.
Discussion
GATA-3 has long been recognized as essential for T cell development, and it is expressed with only modest quantitative changes throughout T cell development. We show in the present study that it is profoundly dose-dependent in its action. Important qualitative effects on lineage choice, differentiation, and gene targeting can emerge from increased levels of GATA-3 expression; excess GATA-3 aborts T cell development, even when the excess is small (12, 14, 44) . However, in its roles to promote T lineage fates, GATA-3 has been studied exclusively in an all-or-none fashion (3, 7, 10, 11) . In this study, we have used a variety of developmental conditions, differing in precursor sources, developmental timings, and durations of perturbation, to reduce GATA-3 dosage, in order to show that the gentle increase in GATA-3 expression from ETP/DN1 stage to DN2b stage can have significant regulatory consequences. First, T cell precursors need GATA-3 to rise beyond its ETP/DN1 level to generate correctly programmed DN2 and DN3 cells. These higher levels of GATA-3 also antagonize PU.1, which may limit myeloid potential. Second, even at low levels, GATA-3 is an acutely sensiqPCR primer sets used to measure the deletion of Gata3 locus used in (F). G3-F/G3-R1 primer set detects the floxed Gata3 alleles. G3-F/G3-R2 primer set detects deleted Gata3 alleles. (H) Deletion of Bcl11b in the samples was measured as in (F), except showing ratio of deleted allele to GAPDH gene signal. The Bcl11b deleted product can only be generated from genotypes containing a Bcl11b floxed gene (here, BxG), but importantly deletion (Bcl11b deleted/ GAPDH ratio of .0.1) shows no correlation with NK or B fate of the cells. (I) qPCR primer sets used to measure the deletion of Bcl11b locus in (H). tive repressor of B cell developmental potential. Thus, its early induction in thymic immigrants is properly timed to explain the early exclusion of B cell potential (51) (reviewed in Refs. [52] [53] [54] . Dose reduction of GATA-3 by shRNA severely impacted normal population dynamics of DN1 cells and also prevented the development of normal DN2 and DN3 cells from prethymic or DN1/ETP precursors. These effects were initially weak but became increasingly pronounced during a period of days. The surviving DN2 cells with reduced GATA-3 activity were abnormal in several respects, with uncoupling of CD44 and c-Kit regulation and loss of control of both DN1-specific genes and DN3-specific genes. Even with these effects of GATA-3 knockdown, the cells were evidently strongly selected for retention of some residual GATA-3 expression. Cre-mediated deletion of both copies of the Gata3 gene had catastrophic effects on viability as long as the cells were maintained in Notch-signaling conditions to support T cell development. It was clearly only the cells with full deletion of Gata3 that reacquired access to the B cell pathway.
Explaining these effects on ETP/DN1 survival, DN2-DN3 progression competence, and access to the B and myeloid fates at a molecular level will require further research, but our results present a wealth of provocative candidate mediators. The early T cell program includes both positive and negative regulatory targets of GATA-3 action, and our results imply that these have different patterns of response to differing degrees of GATA-3 dose reduction. Some genes respond rapidly to any decrease in GATA-3 expression level, and many of these are genes that appear to be relieved from repression when GATA-3 doses drop. Although the magnitudes of the effects are initially modest, these include three genes encoding transcription factors of great developmental significance: the progenitor cell and myeloid regulatory factor PU.1; the closely related factor that collaborates with PU.1 in B cell development, SpiB; and the indispensable lymphoid progenitor factor Bcl11a. The repressive effect of GATA-3 on SpiB supports earlier evidence that SpiB/GATA-3 antagonism can control T cell versus plasmacytoid dendritic cell fate determination in human precursors (55) . Likely positive regulatory targets of GATA-3 are less enriched for putative regulatory genes but include genes encoding Ets1 and Bcl11b, two transcription factors that play prominent roles in T lineage commitment and in the DN3 state. However, these genes responded more slowly to the decrease of GATA-3 expression than did SpiB, PU.1, and Bcl11a. Many of the targets most rapidly downregulated by loss of GATA-3 were in fact genes associated with ILC2 cells and mature GATA-3 + effector T cells (12, 47, 48) , clearly expressed in the normal DN2 cells but not previously associated with early T cell developmental functions. It will be very interesting to determine whether Il9r and Il17rb (encoding a chain of the IL-25 receptor) are functionally important in early T lineage development.
ChIP-seq data from two groups have provided maps of GATA-3 binding sites across the genome in thymocytes (12, 13) . Unfortunately, these peak patterns in themselves turn out to be poor predictors of the genes most sensitive to acute GATA-3 perturbation. Some likely positive target genes with particularly strong GATA-3 binding such as Zfpm1, encoding the GATA factor partner FOG1, were completely insensitive to the shRNA and were only affected by a complete deletion of the Gata3 gene. More sensitive targets, both positive and negative, were often only weakly bound by GATA-3 in vivo, when binding was detected at all. Although some of these genes may be indirectly regulated by GATA-3, the very short time points we used were specifically designed to limit indirect effects. Furthermore, the very limited number of transcription factor genes affected at all, and the generally weak effects on those regulatory genes seen at 18-20 h, makes them unlikely candidates for mediating the GATA-3 effects. Thus, although technical factors could be relevant, it is possible that sites with strong GATA-3 occupancy in fact have too high an affinity to be affected by 2-to 3-fold dose reductions. In this case, the molecular mechanisms underlying the potent developmental impact of GATA-3 knockdown must be sought among genes with weak, rapidly exchanging GATA-3 binding sites.
In agreement with our previous results of GATA-3 overexpression, GATA-3 loss of function did not have a clear-cut impact on global Notch signaling; some Notch target genes, including HEBalt and Dtx1, were even somewhat enhanced in expression. However, there are a number of indirect pathways through which GATA-3 could be collaborating with Notch signals. Our results confirm that GATA-3 is a restraining negative regulator of PU.1 levels in early thymocytes when expressed at its normal physiological level as well as when overexpressed. This means it can protect Notch signaling from PU.1 inhibition and also play a role in the eventual extinction of myeloid potential during commitment. The need for GATA-3 to promote accurate DN2-DN3 progression may also be reflected through its specific importance to induce Bcl11b and Ets1 expression as well. The impact of GATA-3 on ETP/DN1 viability could reflect its positive role in c-Kit gene expression, but our data show that this interpretation can be complicated by the disjunction of c-Kit and CD44 developmental regulation when GATA-3 is removed. Other GATA-3-regulated genes are predicted to encode PHD domain and chromobox chromatin modifiers, which opens a wide range of possibilities for regulating survival and self-renewal. Strikingly, however, the trio of repressed genes Bcl11a, Spi1, and SpiB, whether direct or indirect targets, suggests a pathway through which loss of GATA-3 could simultaneously relieve multiple constraints on the B cell program. It will be of great interest to test these hypotheses.
The distinct dosage thresholds for different critical GATA-3 effects clarify the position of GATA-3 in a T cell commitment network (Fig. 9E) . Our results imply that the rising level of GATA-3 first excludes the B cell option, then enables T lineage genes to be turned on, then provides quantitative control over the silencing of PU.1 and myeloid options. Even before helping to activate a definitive T cell program, low-level GATA-3 becomes essential for viability of the earliest T cell precursors. The stagespecific effects of G3-3W shRNA on viability indicate a likely threshold mechanism: even the weak effect of shRNA may push GATA-3 below this threshold when starting from the low levels in ETP/DN1 cells, but not from higher DN2 levels. However, higher, DN2-stage levels of GATA-3 are needed in full to arm cells for competence in developmental progression. Our results confirm that GATA-3 is required to prevent B lineage access, even after T lineage differentiation has begun, through mechanisms that are complementary to, but distinct from, those mediated by Bcl11b (11, 20, 50, 53) . In summary, GATA-3 at the DN2 stage is revealed to be a critically dose-dependent regulator of both T lineage progression and unique aspects of T lineage commitment.
(representative of two independent experiments). Concordant results were obtained in an additional experiment under different culture conditions (not shown).
(E) Natural changes in GATA-3 levels cross distinct developmental dose thresholds. Schematic of effects from the present study and in other work is shown (3, 7, 11, 14, 44) . Red lines indicate thresholds seen in absence of Notch signaling; blue lines, thresholds seen in presence of Notch signaling; light blue zone, permissive for T lineage entry; and darker blue indicates permissive for full T cell commitment.
